



Innovative Medicines Initiative

Brussels, 18 May 2010
IMI/KDR/DOC/2010-527

PRESS RELEASE

High profile leaders in pharma sector join Innovative Medicines Initiative Governing Board

BRUSSELS (Belgium) – Roch Doliveux, Chief Executive Officer of the biopharmaceutical company UCB, has joined the Governing Board of the Innovative Medicines Initiative Joint Undertaking (IMI JU). IMI JU also welcomes Salah-Dine Chibout (Global Head Investigative Toxicology, Novartis) and David Roblin (Senior Vice President, Head of Research, Sandwich Laboratories, Pfizer) into its Board – each of them key players in global pharmaceutical research and development.

'We are pleased that the industry confirms its commitment to IMI by delegating high profiles to the IMI Governing Board', said Michel Goldman, Executive Director of IMI JU. 'The strong support of its founding partners gives IMI the critical mass and the impetus to improve the environment for biopharmaceutical research and development in Europe. With the first fifteen research projects ongoing and a second set of nine project grants to be awarded this summer, IMI is realising its mission of fostering innovative collaborations between academia, SMEs, regulatory agencies, patient organisations and the industry.'

The Innovative Medicines Initiative Joint Undertaking is a public-private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Through its innovative funding scheme, IMI supports more efficient drug discovery and the development of safer and better medicines for patients. The total IMI budget for the period 2008-2017 is €2 billion, including €1 billion contributed by the European Commission's Seventh Framework Programme and €1 billion provided, mainly as in-kind contributions, by the industry.

The members of the IMI Governing Board are:

- | | | |
|-------------------------|---|---------------------|
| • Brian Ager | Director General | EFPIA |
| • Franco Biscontin | Director Resources, DG RTD | European Commission |
| • Salah-Dine Chibout* | Global Head Investigative Toxicology, Deputy
Head Translational Sciences Europe | Novartis |
| • Roch Doliveux* | Chief Executive Officer | UCB |
| • Ruxandra Draghia-Akli | Director Health, DG RTD | European Commission |
| • Carlo Incerti | Head of R&D Europe | Genzyme |
| • Georgette Lalis | Director Consumer Goods, DG ENTR | European Commission |
| • David Roblin* | Senior Vice President
Head of Research and Site Director,
Sandwich Laboratories | Pfizer |
| • Andrzej Jan Rys | Director Public Health and Risk assessment,
DG SANCO | European Commission |
| • X (to be appointed) | | European Commission |

Carlo Incerti has been elected as Chair and Ruxandra Draghia-Akli as Vice-Chair.

* Newly appointed in the IMI Governing Board.

Upcoming IMI events:

- 14 and 15 June 2010: IMI Stakeholder Forum in Brussels Expo.
- End of July 2010: final selection of 9 projects following IMI's 2nd Call for proposals.

More info: www.imi.europa.eu



Contact: Kim De Rijck, IMI External Relations Manager, +32 (0)2 221.81.83



Innovative Medicines Initiative (IMI)
Postal mail: IMI JU, COV2, Office 14/121 1049 Brussels
Visiting address: Covent Garden, Place Rogier 16, 1210 Brussels
tel: +32 (0)2-221 81 81 – fax: +32 (0)2-221 81 74

